vTv Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
vTv Therapeutics Inc. (VTVT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.13% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-10
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.13%, a 5.28% decline from fiscal 2024.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.36%, a 5.42% decline from fiscal 2023.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.61%, a 6.96% increase from fiscal 2022.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.31%, a 221.64% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2025-12-31 | 4.13% 10-K · filed 2026-03-10 |
| 2024-12-31 | 4.36% 10-K · filed 2026-03-10 |
| 2023-12-31 | 4.61% 10-K · filed 2026-03-10 |
| 2022-12-31 | 4.31% 10-K · filed 2025-03-20 |
| 2021-12-31 | 1.34% 10-K · filed 2024-03-13 |